The discovery of ocular proteomic biomarkers can provide new insights into the pathogenesis of specific ocular diseases and accelerate the process of developing related drugs. Through eye qualitative proteomics, eye quantitative proteomics, and eye-targeted proteomics, Ace Therapeutics' bioanalytical team discovers target proteins and identifies potential ocular proteomic biomarkers.
Proteomics is a powerful tool that has been widely used in ophthalmology to understand changes at biochemical levels, discover associated biomarkers, and determine the success of clinical interventions. Ocular proteomics, as an emerging proteomics, offers many new opportunities for discovery and has the potential to provide new insights into the pathogenesis of specific ocular diseases. Ocular proteomics studies allow researchers to identify and quantify dysregulated proteins in biological specimens in a hypothesis-free manner. Understanding dysregulated protein pathways could shed light on the pathogenesis of the disease. Tears have been shown to be a source of eye and systemic disease biomarkers, and tears with a protein concentration of 8-10 mg/mL have attracted attention as a possible source of ocular disease biomarkers that contribute to early diagnosis, prognosis and monitoring of diseases, and offer the potential for the development of new therapies.
Fig. 1. The workflow of the sample preparation for tear proteomic analysis. (Huang Z, et al., 2018)
As a comprehensive ophthalmology solution company, Ace Therapeutics is committed to discovering beneficial biomarkers in the ocular matrix (tears, vitreous humor, aqueous humor, etc.) to help customers design precise and personalized drug development faster project. Our bioanalytical team has extensive experience in the development and validation of biomarker assays to identify relevant biomarkers and predict the progression of ocular diseases by monitoring proteins of interest and their post-translational status.
Ace Therapeutics uses advanced proteomics technology to find relevant biomarkers in samples, SELDI-TOF-MS screens biomarkers related to eye diseases, RP-HPLC separates and purifies samples, and uses MALDI-TOF-MS to track target proteins, to identify potentially relevant ocular protein markers by LC-MS/MS.
At Ace Therapeutics, our scientists will interrogate your biological samples to identify potential biomarkers that a proteomic profile may yield, no matter what type of sample you provide.
Ace Therapeutics' team is dedicated to serving global customers. Our scientists are always ready to provide high-quality eye proteomic biomarker solutions to global customers. If you have questions about the content of this service, please feel free to contact us. We look forward to hearing from you.
Reference